TT-OAD2
Code | Size | Price |
---|
TAR-T13218-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T13218-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
TT-OAD2 is a non-peptide agonist of glucagon-like peptide-1 (GLP-1) receptor (EC50: 5 nM), with the potential for diabetes treatment.
CAS:
2382719-60-8
Formula:
C50H49Cl4N3O6
Molecular Weight:
929.75
Purity:
0.98
SMILES:
CC[C@@H](C1=CC=CC=C1)N2[C@@H](CC3=CC(OC[C@@](C4=CC=C(C=C4)OCC5=CC(Cl)=C(C=C5)Cl)([H])O6)=C6C=C3C2)C(N[C@H](C(O)=O)CC7=CC=C(C8=CC=NC(C)=C8C)C=C7)=O.Cl.Cl
References
Zhao P, et al. Activation of the GLP-1 receptor by a non-peptidic agonist. Nature. 2020 Jan;577(7790):432-436.
Transtech Pharma, et al. Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof. WO2010114824A1.